Filtered By:
Cancer: Astrocytoma
Management: WHO
This page shows you your search results in order of date.
Order by Relevance | Date
Total 259 results found since Jan 2013.
< em > CDKN2A/B < /em > Homozygous Deletions in Astrocytomas: A Literature Review
Curr Issues Mol Biol. 2023 Jun 22;45(7):5276-5292. doi: 10.3390/cimb45070335.ABSTRACTGenomic alterations of CDKN2A and CDKN2B in astrocytomas have been an evolving area of study for decades. Most recently, there has been considerable interest in the effect of CDKN2A and/or CDKN2B (CDKN2A/B) homozygous deletions (HD) on the prognosis of isocitrate dehydrogenase (IDH)-mutant astrocytomas. This is highlighted by the adoption of CDKN2A/B HD as an essential criterion for astrocytoma and IDH-mutant central nervous system (CNS) WHO grade 4 in the fifth edition of the World Health Organisation (WHO) Classification of Central Nervo...
Source: Mol Biol Cell - July 28, 2023 Category: Molecular Biology Authors: Alexander Yuile Laveniya Satgunaseelan Joe Q Wei Michael Rodriguez Michael Back Nick Pavlakis Amanda Hudson Marina Kastelan Helen R Wheeler Adrian Lee Source Type: research
Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study
CONCLUSION: Anlotinib had a low incidence of AEs and good safety in the treatment of recurrent high-grade glioma. Moreover, it showed good short-term effectiveness and significantly prolonged the PFS of patients, which may become a promising therapeutic option for recurrent high-grade glioma and lay a foundation for further clinical studies.PMID:37435019 | PMC:PMC10331188 | DOI:10.1177/11795549231175714
Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Jun Yin Wenya Yin Linlin Zheng Yimin Li Cheng Luo Shuo Zhang Lei Duan Hang Zhou Kai Cheng Jinyi Lang Ke Xu Source Type: research
Galectin-3 Mediates Tumor Progression in Astrocytoma by Regulating Glycogen Synthase Kinase-3 β Activity
This study aims to validate the correlation between the clinical outcomes and protein expression of galectin-3/GSK3B in astrocytoma. Immunohistochemistry staining was performed to detect galectin-3/GSK3B protein expression in patients with astrocytoma. The Chi-square test, Kaplan-Meier evaluation, and Cox regression analysis were used to determine the correlation between clinical parameters and galectin-3/GSK3B expression. Cell proliferation, invasion, and migration were compared between a non-siRNA group and a galectin-3/GSK3B siRNA group. Protein expression in galectin-3 or GSK3B siRNA-treated cells was evaluated using w...
Source: Current Issues in Molecular Biology - May 15, 2023 Category: Molecular Biology Authors: Hung-Pei Tsai Chien-Ju Lin Ann-Shung Lieu Yi-Ting Chen Tzu-Ting Tseng Aij-Lie Kwan Joon-Khim Loh Source Type: research
Update on quality assurance in neuropathology: Summary of the round robin trials on TERT promoter mutation, H3-3A mutation, 1p/19q codeletion, and KIAA1549::BRAF fusion testing in Germany in 2020 and 2021
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301547. Online ahead of print.ABSTRACTWe previously reported on the first neuropathological round robin trials operated together with Quality in Pathology (QuIP) GmbH in 2018 and 2019 in Germany, i.e., the trials on IDH mutational testing and MGMT promoter methylation analysis [1]. For 2020 and 2021, the spectrum of round robin trials has been expanded to cover the most commonly used assays in neuropathological institutions. In addition to IDH mutation and MGMT promoter methylation testing, there is a long tradition for 1p/19q codeletion testing relevant in the context of the d...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Sandra Pohl Lora Dimitrova Maja Grassow-Narlik Korinna J öhrens Till Acker Hildegard Dohmen Jochen Herms Mario Dorostkar Christian Hartmann Martin Hasselblatt Manuela Neumann Guido Reifenberger J örg Felsberg Ulrich Sch üller Saida Zoubaa Julia Lorenz Source Type: research
